Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
First-line Treatment Phase	STARTED	Panitumumab Plus Chemotherapy	56
First-line Treatment Phase	STARTED	Chemotherapy Alone	57
First-line Treatment Phase	Received Study Medication	Panitumumab Plus Chemotherapy	56
First-line Treatment Phase	Received Study Medication	Chemotherapy Alone	55
First-line Treatment Phase	COMPLETED	Panitumumab Plus Chemotherapy	51
First-line Treatment Phase	COMPLETED	Chemotherapy Alone	49
First-line Treatment Phase	NOT COMPLETED	Panitumumab Plus Chemotherapy	5
First-line Treatment Phase	NOT COMPLETED	Chemotherapy Alone	8
Second-line Treatment Phase	STARTED	Panitumumab Plus Chemotherapy	0
Second-line Treatment Phase	STARTED	Chemotherapy Alone	30
Second-line Treatment Phase	COMPLETED	Panitumumab Plus Chemotherapy	0
Second-line Treatment Phase	COMPLETED	Chemotherapy Alone	27
Second-line Treatment Phase	NOT COMPLETED	Panitumumab Plus Chemotherapy	0
Second-line Treatment Phase	NOT COMPLETED	Chemotherapy Alone	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00454779/flow